Significance of BA/BE Studies

This section provides recommendations to the applicants, who undertake bioequivalence studies and/or who wish to request a waiver of in vivo bioequivalence studies for immediate release solid oral dosage forms.  Guidance here in explains how the bioequivalence studies should be performed, and when bio waivers can be requested in the context of the WHO Prequalification of Medicines Programme. Data on bioequivalence provide a bridge between two or more pharmaceutical equivalents when safety and efficacy data are available for one of the products, but not for the other. For multisource products bioequivalence studies, conferences are necessary to ensure therapeutic equivalence and interchange ability of the products. Bioequivalence can also be demonstrated by comparative clinical studies, pharmacokinetic studies or appropriate in vitro studies.

 

  • Analysis of BA/BE by oral vs parentral
  • Criterion for bioequivalence confidence interval approach
  • Parametric vs non-parametric tests
  • Bioequivalence of endogenous substances
  • Plasma concentration vs time curve (AUC) based dosing
  • Adverse drug reactions
  • In narrow therapeutic index drugs

Related Conference of Significance of BA/BE Studies

December 14-14, 2020

2nd Pathology and Infectious Disease Conference

Dubai, UAE
March 28-29, 2021

11th Glycobiology World Congress

Vienna, Austria
April 24-24, 2021

2nd International Conference on Nucleic Acids

London, UK
June 11-12, 2021

25th Global Congress on Biotechnology

Berlin, Germany
September 13-14, 2021

17th World Congress on Structural Biology

Prague, Czech Republic
September 27-28, 2021

25th European Biotechnology Congress

Dublin, Ireland

Significance of BA/BE Studies Conference Speakers

Recommended Sessions

Related Journals

Are you interested in